Arvinas, Inc.
ARVN · NASDAQ
Company research
Arvinas, Inc. (NASDAQ: ARVN) is a clinical-stage biopharmaceutical company headquartered in New Haven, Connecticut, dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of targeted protein degradation therapies. Founded in 2013 by Yale University researcher Dr. Craig Crews, the company pioneers its proprietary PROTAC (PROteolysis TArgeting Chimera) platform, which harnesses the body's natural ubiquitin-proteasome system to selectively degrade and remove disease-causing proteins — including previously "undruggable" targets. Arvinas's clinical pipeline includes vepdegestrant (targeting the estrogen receptor for ER+/HER2- breast cancer), ARV-102 (targeting LRRK2 for neurodegenerative disorders), ARV-393 (targeting BCL6 for non-Hodgkin Lymphoma), and ARV-806 (targeting KRAS G12D for pancreatic and colorectal cancers), with the company recently achieving a significant milestone through the FDA approval of its first drug, Veppanu. Arvinas maintains strategic collaborations with major pharmaceutical partners including Pfizer, Genentech, F. Hoffmann-La Roche, and Bayer AG to co-develop and advance its innovative therapeutic assets.
Research reports
This quantitative company analysis page characterizes Arvinas as a small‑cap biotech trading about 37.5% above its base fair value estimate, with moderate scores on profitability and health but a short estimated cash runway around 6.3 months and explicit flags that additional financing is likely, underscoring valuation and balance‑sheet risk despite strong R&D focus.
KoalaGains · May 4, 2026Arvinas, Inc. (ARVN) Stock Analysis & Key Metrics (ARVN)This comprehensive equity research report presents Arvinas as a high‑risk, high‑reward clinical‑stage PROTAC platform with strong cash reserves and minimal debt, a negative enterprise value suggesting the market is undervaluing its science, and a differentiated pipeline led by vepdegestrant and bavdegalutamide, while stressing that binary clinical trial outcomes and intense competition make position sizing and risk management critical.